Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
Gyre Therapeutics (NASDAQ: GYRE), a commercial-stage biopharmaceutical company focused on fibrosis-first therapies, has appointed Dr. Dan Weng to its Board of Directors effective August 18, 2025.
Dr. Weng brings nearly 40 years of experience in managing global clinical trials and currently serves as President and CEO of Medelis, Inc. His extensive background includes executive positions at major CROs and research roles at prestigious institutions including Harvard Medical School and Massachusetts General Hospital.
The appointment comes at a strategic time as Gyre aims to expand its commercial reach and advance its multi-national pipeline. Dr. Weng's expertise in regulatory affairs and clinical trial management is expected to support the company's growth initiatives.
Gyre Therapeutics (NASDAQ: GYRE), azienda biofarmaceutica in fase commerciale focalizzata su terapie contro la fibrosi, ha nominato Dr. Dan Weng nel suo Consiglio di Amministrazione con efficacia dal 18 agosto 2025.
Il Dr. Weng porta con sé quasi 40 anni di esperienza nella gestione di studi clinici globali e ricopre attualmente la carica di Presidente e CEO di Medelis, Inc. Il suo percorso professionale comprende ruoli esecutivi in grandi CRO e attività di ricerca presso istituzioni di prestigio come la Harvard Medical School e il Massachusetts General Hospital.
La nomina arriva in un momento strategico, mentre Gyre punta a estendere la propria presenza commerciale e a far progredire il suo portafoglio multinazionale. L’esperienza del Dr. Weng in materia regolatoria e nella gestione di trial clinici è destinata a sostenere le iniziative di crescita dell’azienda.
Gyre Therapeutics (NASDAQ: GYRE), una compañía biofarmacéutica en fase comercial centrada en terapias para la fibrosis, ha nombrado a Dr. Dan Weng como miembro de su Junta Directiva con efecto a partir del 18 de agosto de 2025.
El Dr. Weng aporta casi 40 años de experiencia en la gestión de ensayos clínicos globales y actualmente es Presidente y CEO de Medelis, Inc. Su amplia trayectoria incluye puestos ejecutivos en grandes CRO y labores de investigación en instituciones de prestigio como Harvard Medical School y Massachusetts General Hospital.
El nombramiento se produce en un momento estratégico, mientras Gyre busca ampliar su alcance comercial y avanzar en su cartera multinacional. Se espera que la experiencia del Dr. Weng en asuntos regulatorios y gestión de ensayos clínicos respalde las iniciativas de crecimiento de la compañía.
Gyre Therapeutics (NASDAQ: GYRE)는 섬유화 치료에 주력하는 상업 단계의 바이오제약 기업으로, Dr. Dan Weng을 2025년 8월 18일부로 이사회 이사로 선임했습니다.
Weng 박사는 전 세계 임상시험 관리 분야에서 거의 40년의 경험을 보유하고 있으며 현재 Medelis, Inc.의 회장 겸 CEO로 재직 중입니다. 그의 폭넓은 경력에는 주요 CRO의 경영진 직책과 하버드 의과대학(Harvard Medical School) 및 매사추세츠 종합병원(Massachusetts General Hospital) 등 저명 기관에서의 연구 활동이 포함됩니다.
이번 임명은 Gyre가 상업적 범위를 확장하고 다국적 파이프라인을 진전시키려는 전략적 시점에 이루어졌습니다. Weng 박사의 규제 및 임상시험 관리 전문성은 회사의 성장 추진을 지원할 것으로 기대됩니다.
Gyre Therapeutics (NASDAQ: GYRE), société biopharmaceutique en phase commerciale axée sur des thérapies ciblant la fibrose, a nommé Dr. Dan Weng au sein de son conseil d'administration, à compter du 18 août 2025.
Le Dr Weng apporte près de 40 ans d'expérience dans la gestion d'essais cliniques à l'échelle mondiale et occupe actuellement les fonctions de président et CEO de Medelis, Inc. Son parcours comprend des postes de direction au sein de grandes CRO et des activités de recherche dans des institutions prestigieuses telles que la Harvard Medical School et le Massachusetts General Hospital.
Cette nomination intervient à un moment stratégique, alors que Gyre cherche à étendre sa portée commerciale et à faire progresser son portefeuille multinational. L'expertise du Dr Weng en matière réglementaire et de gestion des essais cliniques devrait soutenir les initiatives de croissance de l'entreprise.
Gyre Therapeutics (NASDAQ: GYRE), ein kommerziell tätiges Biopharmaunternehmen mit Schwerpunkt auf fibroseorientierten Therapien, hat Dr. Dan Weng mit Wirkung zum 18. August 2025 in seinen Vorstand berufen.
Dr. Weng bringt nahezu 40 Jahre Erfahrung in der Leitung globaler klinischer Studien mit und ist derzeit Präsident und CEO von Medelis, Inc. Zu seinem umfangreichen beruflichen Hintergrund zählen Führungspositionen bei großen CROs sowie Forschungsaufenthalte an renommierten Institutionen wie der Harvard Medical School und dem Massachusetts General Hospital.
Die Berufung erfolgt zu einem strategischen Zeitpunkt, da Gyre seine kommerzielle Reichweite ausbauen und seine multinationale Pipeline vorantreiben will. Dr. Wengs Expertise in regulatorischen Belangen und im Management klinischer Studien wird voraussichtlich die Wachstumsinitiativen des Unternehmens unterstützen.
- Addition of seasoned executive with 40 years of clinical trial management experience
- Strategic appointment to support commercial expansion and pipeline advancement
- Strengthened board expertise in regulatory affairs and global clinical operations
- None.
SAN DIEGO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced the appointment of Dan Weng, M.D., to its Board of Directors (the “Board”) effective August 18, 2025.
Dr. Weng has served as President and Chief Executive Officer of Medelis, Inc., a specialty oncology contract research organization (“CRO”), since 2018. From 2013 to 2017, he served as Chairman, President, and Chief Executive Officer of EPS International Holding Co., a subsidiary of EPS Holdings, Inc., a global CRO where he oversaw significant growth, both organically and through M&A in Asia, and played an active role in corporate strategy and investor relations. Prior to that, Dr. Weng held executive positions at international CROs including MedPace, Inc., ICON Plc, PharmaNet Development Group, and Quintiles Translational Corp. Dr. Weng also held research positions at Harvard Medical School, Massachusetts General Hospital, and the University of California.
Dr. Weng holds an M.D. from the Tongji Medical University, and an M.A. in Health Planning, Policy and Management from the University of Leeds.
“We are pleased to welcome Dr. Weng to our Board at this pivotal time in Gyre’s evolution. Dan brings nearly four decades of experience in managing global clinical trials across a range of therapeutic areas,” said Ping Zhang, Executive Chairman and Interim Chief Executive Officer of Gyre. “His strategic insight and extensive regulatory experience will be invaluable as we continue to expand our commercial reach and advance our multi-national pipeline.”
About Gyre Pharmaceuticals
Gyre Pharmaceuticals is a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. Its flagship product, ETUARY® (Pirfenidone capsule), was the first approved treatment for IPF in the PRC in 2011 and has maintained a prominent market share (2024 net sales of
About Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the United States. Gyre’s strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People’s Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY®, and development programs for F573, F528, and F230.
For Investors:
David Zhang
Gyre Therapeutics
david.zhang@gyretx.com
FAQ
Who is Dan Weng and what is his role at Gyre Therapeutics (NASDAQ: GYRE)?
What is Dr. Dan Weng's professional background before joining Gyre Therapeutics' board?
How will Dr. Weng's appointment benefit Gyre Therapeutics?
What is Gyre Therapeutics' main business focus?
